Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
Afsaneh ShiraniAnne H CrossOlaf StüvePublished in: Therapeutic advances in neurological disorders (2024)
Our findings suggest a potential consideration for repurposing anti-diabetic weight loss-inducing drugs including semaglutide, dulaglutide, and liraglutide (glucagon-like peptide-1 receptor agonists), empagliflozin (sodium-glucose cotransporter-2 inhibitor), and metformin (biguanide), for MS. This warrants validation through rigorous methodologies and prospective studies.
Keyphrases
- weight loss
- multiple sclerosis
- adverse drug
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- white matter
- type diabetes
- mass spectrometry
- glycemic control
- ms ms
- emergency department
- wound healing
- weight gain
- obese patients
- human health
- drug induced
- adipose tissue
- body mass index
- electronic health record
- climate change
- skeletal muscle